

ASTHMA

Comment on “An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness”

Carlos A. Penno¹, Nathalie Wack², Claire Laguerre¹, Franziska Hasler², Shin Numao³, Till A. Röhn^{2*}

Increased airway hyperresponsiveness and epithelial remodeling in asthmatic LTA₄H-KO mice may be mediated by CysLTs rather than elevated tripeptide PGP.

The recent article by Patel *et al.* (1) characterizes the biological response of an allergic pulmonary inflammation on the background of leukotriene A₄ hydrolase (LTA₄H)-deficient mice. The authors demonstrate that, although many parameters of inflammation were reduced in the absence of LTA₄H, the mice exhibited increased airway resistance, airway remodeling, and goblet cell activation.

Work from this group previously suggested that accumulation of the tripeptide proline-glycine-proline (PGP) in the absence of LTA₄H would lead to enhanced neutrophilic inflammation in models of pulmonary infection (2, 3); in this model of sterile allergic inflammation, however, no such enhanced neutrophilic inflammation could be observed. Our recent publication demonstrated that PGP is actually not chemotactic for neutrophils in LTA₄H knockout (KO) mice nor in human cells and provides an explanation for the observations by Patel *et al.* on neutrophils in this sterile inflammatory setting (4). Therefore, our conclusion was that the enhanced neutrophil response previously observed in infection models is likely a compensatory immune response to the infection in the absence of LTA₄H rather than driven by PGP elevation.

Similarly, we believe that the observations on airway hyperresponsiveness and epithelial remodeling in this recent article by Patel *et al.* may not be due to the elevation of the PGP peptide but could actually be caused by the effects of the cysteinyl leukotrienes (CysLTs) in asthma, which are known to induce bronchoconstriction, airway remodeling, goblet cell activation, and mucus production (5). It is well known that inhibition of specific enzymes of the arachidonic acid pathway can lead to the elevation of lipid mediators due to pathway shunting. We have observed that absence of LTA₄H can lead to the elevation of CysLTs after stimulation of immune cells in vitro or in inflammatory settings in vivo in LTA₄H KO mice (Fig. 1). It is tempting to speculate that the same may have also occurred in the experimental setting used by Patel *et al.*, particularly because this was observed even clinically with the LTA₄H inhibitor JNJ40929837 by Johnson & Johnson in an asthma clinical trial (6).

The authors did not detect elevated CysLTs in house dust mite (HDM)-challenged LTA₄H KO mice (1). However, this measurement was performed 24 hours after allergen challenge. CysLTs are released very rapidly after allergen challenge and become less abundant thereafter (7). Hence, the elevation of CysLTs may have been missed by just assessing one single timepoint after the challenge.

¹Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. ²Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. ³Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

*Corresponding author. Email: till.roehn@novartis.com

Copyright © 2019
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim
to original U.S.
Government Works

To demonstrate that the observed effect on airway resistance, airway remodeling, and goblet cell activation is actually due to PGP and not due to the well-known effects of CysLTs, the authors should have demonstrated that the effect can also be seen in LTA₄H KO mice that were treated with the CysLT receptor antagonist Montelukast or more ideally a 5-lipoxygenase inhibitor. The latter would allow for the study of elevated PGP without the simultaneous elevation of CysLTs in LTA₄H KO mice.

Although the authors demonstrate that PGP is elevated in bronchoalveolar lavage fluid of LTA₄H KO mice after allergen challenge (1), they never demonstrate that acetyl-PGP is also elevated. In the paper, it is assumed that PGP gets converted into acetyl-PGP in vivo and that this will have similar effects to PGP. However, because this was not directly shown, we question the use of acetyl-PGP as a surrogate to demonstrate the role of PGP. Indeed, taking into account that acetyl-PGP is not degraded by LTA₄H and that knocking out LTA₄H in mice does not influence its abundance (4), the observation that this peptide is not detected in the epithelium of HDM-stimulated mice further validates this concern.

Furthermore, we believe that using the L-arginine-threonine-arginine (RTR) peptide as an antagonist to revert the effects of acetyl-PGP is not an appropriate control either because it has been shown previously that RTR also interferes with the action of other immune mediators signaling via CXCR1 and CXCR2 such as IL-8 (interleukin-8) (8). Hence, any observed immune modulation using this peptide will be a result of polypharmacology and, without additional controls, cannot be deconvoluted into a single pathway, particularly given the fact that acetyl-PGP is not even detectable in HDM-stimulated LTA₄H KO mice.

The authors suggest that the failures of LTA₄H inhibitors in the clinic may be due to PGP elevation. We believe that this conclusion is unsubstantiated, as to our knowledge, so far, only two LTA₄H inhibitors were tested in clinical efficacy trials in patients. The first, compound JNJ40929837 by Johnson & Johnson, was tested in an asthma trial and showed lack of efficacy (6). In this study, it was clinically demonstrated that CysLTs were elevated by LTA₄H inhibition, providing a possible reason for the lack of efficacy because CysLTs are among the main pathological drivers in asthma. The second, compound Acebilustat from Celtaxsys, was tested in cystic fibrosis (CF) and demonstrated a reduction in markers of neutrophilic inflammation (9), as well as a clinically meaningful reduction in inflammatory exacerbations in a 48-week phase 2b study (<http://www.celtaxsys.com/2018/08/02/celtaxsys-announces-results-of-phase-2-trial-showing-clinically-meaningful-improvement-in-pulmonary-exacerbations-in-cystic-fibrosis-patients/>). Although it was previously demonstrated that the levels of PGP are elevated in CF (10),




Fig. 1. LTA₄H KO mice generate elevated levels of cysteinyl leukotrienes during inflammation. (A) Peripheral blood mononuclear cells (PBMCs) of C57/BL6 wild-type and LTA₄H KO littermate mice were stimulated for 30 min with ionophore A23187, and generation of leukotrienes was determined by liquid chromatography tandem mass spectrometry (LC-MS/MS). PBMCs of a pool of five mice per strain were analyzed. Average \pm SEM are shown. (B) Acute sterile peritonitis was induced by intraperitoneal administration of zymosan A particles into C57/BL6 wild-type and LTA₄H KO littermate mice. Four hours after the induction of the inflammatory process, lavages were collected and analyzed for content of leukotrienes by LC-MS/MS. Five animals per group were analyzed, and data are depicted as average \pm SEM. ****** P < 0.01 using the two-tailed Welch's t test comparing wild-type and LTA₄H KO mice. n.d., not detected; LTB₄, leukotriene B₄; LTC₄, leukotriene C₄; LTD₄, leukotriene D₄; LTE₄, leukotriene E₄.

treatment of patients with CF with LTA₄H inhibitors did obviously result in anti-inflammatory effects, indicating that, clinically, there is no relevant effect of PGP elevation as well.

In summary, we believe that the data presented by Patel *et al.* do not unequivocally demonstrate a causative role for PGP in airway hyperresponsiveness and epithelial remodeling. The observed effects may be alternatively explained by the elevation of cysteinyl leukotrienes that are known to cause such effects in airways and can be increased in LTA₄H KO mice. A direct effect of PGP on these lung parameters has not been shown, but instead, acetyl-PGP was used as a surrogate. Acetyl-PGP was not shown to be elevated in HDM-challenged LTA₄H KO mice and is very different from PGP in terms of its biological activity as demonstrated by us and others in the past (4).

REFERENCES AND NOTES

1. D. F. Patel, T. Peiró, A. Shoemark, S. Akthar, S. A. Walker, A. M. Grabiec, P. L. Jackson, T. Hussell, A. Gaggar, X. Xu, J. L. Trevor, J. Li, C. Steele, G. Tavernier, J. E. Blalock, R. M. Niven, L. G. Gregory, A. Simpson, C. M. Lloyd, R. J. Snelgrove, An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness. *Sci. Transl. Med.* **10**, eaaq0693 (2018).
2. S. Akthar, D. F. Patel, R. C. Beale, T. Peiró, X. Xu, A. Gaggar, P. L. Jackson, J. E. Blalock, C. M. Lloyd, R. J. Snelgrove, Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection. *Nat. Commun.* **6**, 8423 (2015).
3. R. J. Snelgrove, P. L. Jackson, M. T. Hardison, B. D. Noerager, A. Kinloch, A. Gaggar, S. Shastry, S. M. Rowe, Y. M. Shim, T. Hussell, J. E. Blalock, A critical role for LTA₄H in limiting chronic pulmonary neutrophilic inflammation. *Science* **330**, 90–94 (2010).
4. S. Numao, F. Hasler, C. Laguerre, H. Srinivas, N. Wack, P. Jäger, A. Schmid, A. Osmont, P. Röthlisberger, J. Houguenad, C. Bergsdorf, J. Dawson, N. Carte, A. Hofmann, C. Markert, L. Hardaker, A. Billich, R. M. Wolf, C. A. Penno, B. Bollbuck, W. Miltz, T. A. Röhn,

Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A₄ hydrolase inhibitors. *Sci. Rep.* **7**, 13591 (2017).

5. W. R. Henderson Jr., G. K. S. Chiang, Y.-t. Tien, E. Y. Chi, Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. *Am. J. Respir. Crit. Care Med.* **173**, 718–728 (2006).
6. W. Barchuk, J. Lambert, R. Fuhr, J. Z. Jiang, K. Bertelsen, A. Fourie, X. Liu, P. E. Silkoff, E. S. Barnathan, R. Thurmond, Effects of JNJ-40929837, a leukotriene A₄ hydrolase inhibitor, in a bronchial allergen challenge model of asthma. *Pulm. Pharmacol. Ther.* **29**, 15–23 (2014).
7. B. B. Vargaftig, M. Singer, Leukotrienes mediate part of Ova-induced lung effects in mice via EGFR. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **285**, L808–L818 (2003).
8. A. H. van Houwelingen, N. M. Weathington, V. Verweij, J. E. Blalock, F. P. Nijkamp, G. Folkerts, Induction of lung emphysema is prevented by L-arginine-threonine-arginine. *FASEB J.* **22**, 3403–3408 (2008).
9. J. S. Elborn, A. Horsley, G. MacGregor, D. Bilton, R. Grosswald, S. Ahuja, E. B. Springman, Phase I studies of acebilustat: Biomarker response and safety in patients with cystic fibrosis. *Clin. Transl. Sci.* **10**, 28–34 (2017).
10. X. Xu, P. L. Jackson, S. Tanner, M. T. Hardison, M. AbdulRoda, J. E. Blalock, A. Gaggar, A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. *PLOS ONE* **6**, e15781 (2011).

Competing interests: We disclose that all authors are current or former employees of and hold company stocks or stock options with Novartis Pharma AG. T.A.R. is a co-author on a published patent on the discovery of LTA₄H inhibitors (US20180170887A.1).

Submitted 17 September 2018

Accepted 29 May 2019

Published 19 June 2019

10.1126/scitranslmed.aav4538

Citation: C. A. Penno, N. Wack, C. Laguerre, F. Hasler, S. Numao, T. A. Röhn, Comment on “An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness”. *Sci. Transl. Med.* **11**, eaav4538 (2019).

Science Translational Medicine

Comment on "An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness"

Carlos A. Penno, Nathalie Wack, Claire Laguerre, Franziska Hasler, Shin Numao and Till A. Röhn

Sci Transl Med 11, eaav4538.
DOI: 10.1126/scitranslmed.aav4538

ARTICLE TOOLS	http://stm.sciencemag.org/content/11/497/eaav4538
RELATED CONTENT	http://stm.sciencemag.org/content/scitransmed/10/455/eaav0693.full
REFERENCES	This article cites 10 articles, 2 of which you can access for free http://stm.sciencemag.org/content/11/497/eaav4538#BIBL
PERMISSIONS	http://www.sciencemag.org/help/reprints-and-permissions

Use of this article is subject to the [Terms of Service](#)

Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works